Some 80% of people who develop Parkinson’s present with this sleep disorder first. Syntara’s treating it

Syntara (ASX:SNT) has today added ~$2 million to its coffers – $1.7M to be exact – after receiving a milestone payment from Parkinson’s U.K. as the final dose of Syntara’s relevant drug SNT-4728 was doled out in an ongoing Phase II clinical trial.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

Disclaimer: This content has been prepared as part of a partnership with Syntara Ltd and is intended for informational purposes only.

The company expects to receive top-line results from the trial in CYQ2 of this year; a further $450,000 is set to head Syntara’s way further along in the trial, again on a milestone basis.

That trial is evaluating Syntara’s SNT-4728 in patients with a REM sleep disorder – called iRBD – but it’s a sleep disorder that stands as “one of the strongest known early indicators of future Parkinson’s disease” and related conditions.

That’s not a loose connection. Syntara reported on Thursday that some 80% of patients who present with iRBD go on to develop Parkinson’s down the line, underscoring the value potential of what Syntara’s got in its portfolio.

To that end, the company highlighted one big pie, all cards in order: the addressable market there is estimated to reflect a value of over A$13 billion.

SNT last traded at 3cps.

Join the discussion: See what HotCopper users are saying about Syntara Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.